Programmed Death-Ligand 1 Immunohistochemistry in Lung Cancer: In what state is this art?

↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Search: WFRF:(Nicholson Andrew G.) > Programmed Death-Li...

Details
MARC

Kerr, Keith M (author)

Programmed Death-Ligand 1 Immunohistochemistry in Lung Cancer : In what state is this art?

Article/chapterEnglish2015

Publisher, publication year, extent ...

2015
printrdacarrier

Numbers

LIBRIS-ID:oai:DiVA.org:uu-279078
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-279078URI
https://doi.org/10.1097/JTO.0000000000000526DOI

Supplementary language notes

Language:English
Summary in:English

Part of subdatabase

SwePubSwePub

Classification

Subject category:ref swepub-contenttype
Subject category:art swepub-publicationtype

Notes

Johan Botling var representant från IASLC Pathology Committee
Therapeutic antibodies to programmed death receptor 1 (PD-1) and its ligand PD-L1 show promising clinical results. Anti-PD-L1 immunohistochemistry (IHC) may be a biomarker to select patients more likely to respond to these treatments. However, the development of at least four different therapeutics, each with a different anti-PD-L1 IHC assay, has raised concerns among pathologists and oncologists alike. This article reviews existing data on the IHC biomarker aspects of studies using these drugs in non-small-cell lung cancer (NSCLC) and considers the challenges ahead, should these drug/IHC assay combinations reach routine practice. For each the known biomarker assays in development, there is a different monoclonal IHC antibody clone, produced by one of two diagnostics companies. Each test requires proprietary staining platforms and uses different definitions of a "positive" test for PD-L1 expression, on tumor cells and, in one test, also on tumor infiltrating immune cells. There are still considerable gaps in our knowledge of the technical aspects of these tests, and of the biological implications and associations of PD-L1 expression in NSCLC, considering heterogeneity of expression, dynamic changes in expression, and prognostic implications among other factors. The International Association for the Study of Lung Cancer Pathology Committee raises the prospect of trying not only to harmonize and standardize testing for PD-L1 by IHC, at least at a technical level, but also, ideally, as a predictive marker, to facilitate availability of this test and a promising treatment for patients with NSCLC.

Subject headings and genre

MEDICIN OCH HÄLSOVETENSKAP Klinisk medicin Klinisk laboratoriemedicin hsv//swe
MEDICAL AND HEALTH SCIENCES Clinical Medicine Clinical Laboratory Medicine hsv//eng
MEDICIN OCH HÄLSOVETENSKAP Medicinska och farmaceutiska grundvetenskaper hsv//swe
MEDICAL AND HEALTH SCIENCES Basic Medicine hsv//eng
Pathology
Patologi

Added entries (persons, corporate bodies, meetings, titles ...)

Tsao, Ming-Sound (author)
Nicholson, Andrew G (author)
Yatabe, Yasushi (author)
Wistuba, Ignacio I (author)
Hirsch, Fred R (author)
Botling, JohanIASLC Pathology Committee(Swepub:uu)johanbot (author)
IASLC Pathology Committee (creator_code:org_t)

Related titles

In:Journal of Thoracic Oncology10:7, s. 985-9891556-08641556-1380

Internet link

Find in a library

Journal of Thoracic Oncology (Search for host publication in LIBRIS)

To the university's database

Find more in SwePub

By the author/editor: Kerr, Keith M; Tsao, Ming-Sound; Nicholson, Andre ...; Yatabe, Yasushi; Wistuba, Ignacio ...; Hirsch, Fred R; show more...; Botling, Johan; show less...

About the subject

MEDICAL AND HEALTH SCIENCES: MEDICAL AND HEAL ...; and Clinical Medicin ...; and Clinical Laborat ...

MEDICAL AND HEALTH SCIENCES: MEDICAL AND HEAL ...; and Basic Medicine

Articles in the publication: Journal of Thora ...

By the university: Uppsala University

Search outside SwePub

Extend your search to:: Google; Google Book Search; Google Scholar

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

LIBRIS.kb.se